Beam Therapeutics Inc. Common Stock

BEAMNASDAQ • USD
22.83 USD
↘ 1.20 (4.99%)AT CLOSE (03:59 PM EST)
23.04
↗ 0.22 (0.94%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
23.04
↗ 0.22 (0.94%)
🔴Market: CLOSED

BEAM is currently priced at $22.83. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On valuation, BEAM trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 13, 2026.

Open?$24.03
High?$24.06
Low?$22.81
Prev. Close?$24.03
Volume?2.0M
Avg. Volume?1.9M
VWAP?$23.26
Rel. Volume?1.06x
Bid / Ask
Bid?$22.90 × 100
Ask?$24.00 × 100
Spread?$1.10
Midpoint?$23.45
Valuation & Ratios
Market Cap?2.4B
Shares Out?103.5M
Float?82.0M
Float %?79.4%
P/E Ratio?N/A
P/B Ratio?2.48
EPS?-$1.03
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Employees
540
Market Cap
2.4B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2020-02-06
Address
26 LANDSDOWNE STREET
CAMBRIDGE, MA 02139
Phone: 857-327-8775
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
47
Momentum?
3
Short Sent.?
30
Piotroski F-Score?1/9Weak
Altman Z-Score?2.31Grey
Confidence?69%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?31.82%Squeeze Risk
Short Interest?26.1M
Days to Cover?13.7
Free Float82.0M
Avg Daily Volume1.9M
Settlement Date2026-10-30
Financial Health
Current Ratio?13.00Strong
Quick Ratio?13.00Strong
Cash Ratio?2.60Strong
Debt/Equity?0.11Low
ValuationFAIRLY VALUEDvs 5 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
83
S&P
65
2.48CHEAP▾
P/S?
Peers
83
S&P
3
16.11HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-6.1CHEAP▾
EV/Sales?
Peers
83
S&P
3
15.34HIGH▾
Returns & Efficiency
ROE?
S&P
9
-11.2%WEAK▾
ROA?
S&P
3
-8.4%WEAK▾
Cash Flow & Enterprise
FCF?$-398237000
Enterprise Value?$2.2B
Fundamentals ratios updated end of day